These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 14760089

  • 1. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.
    Clin Cancer Res; 2004 Jan 15; 10(2):658-67. PubMed ID: 14760089
    [Abstract] [Full Text] [Related]

  • 2. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R.
    Mol Cancer Ther; 2003 Apr 15; 2(4):345-51. PubMed ID: 12700278
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.
    J Natl Cancer Inst; 2003 Dec 17; 95(24):1825-33. PubMed ID: 14679152
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 17; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 10. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G.
    Br J Cancer; 2002 May 06; 86(9):1518-23. PubMed ID: 11986789
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 16. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
    Albitar L, Laidler LL, Abdallah R, Leslie KK.
    Mol Cancer Ther; 2005 Dec 15; 4(12):1891-9. PubMed ID: 16373704
    [Abstract] [Full Text] [Related]

  • 17. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C.
    Int J Radiat Oncol Biol Phys; 2003 Mar 01; 55(3):713-23. PubMed ID: 12573759
    [Abstract] [Full Text] [Related]

  • 18. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
    Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M.
    J Cancer Res Clin Oncol; 2003 Mar 01; 129(3):165-74. PubMed ID: 12712332
    [Abstract] [Full Text] [Related]

  • 19. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T.
    Lung Cancer; 2003 Oct 01; 42(1):35-41. PubMed ID: 14512185
    [Abstract] [Full Text] [Related]

  • 20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.